-
CancelDate：2020-11
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=516Huiyihuiying (the “Company”) a leader in medical imaging artificial intelligence, announced that it has successfully completed its latest round (Series C2) of hundreds of millions of RMB in financing, one of the largest financings in the healthcare AI industry in China. This round of financing included new investors Shougang Fund, Sinopharm Junbai, and Kunjian Xintai, and existing shareholders including CDH Investments, Datai Capital, and Lanchi Ventures. CEC Capital Group served as the exclusive financial advisor of Huiyihuiying in this transaction.
-
CancelDate：2020-11
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=530Beijing Megarobo Technologies Co., Ltd. (“Megarobo” or the “Company”) has recently completed a USD 30 million Series B financing round. This round of financing was led by Sinovation Ventures. Followers in the round included Liando Investment and existing shareholders Joy Capital and Robert Bosch Venture Capital. CEC Capital Group acted as the exclusive financial advisor of Megarobo in this transaction. Proceeds from this round will primarily be used to expand Megarobo’s core business, R&D efforts, the Company’s laboratory facilities, and to continue to build up the Company’s core capabilities in the field of life science automation.
-
Cancel -
CancelDate：2020-10
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=5043DMed Diagnostic (the “Company”), a leader in the field of accurate tumor diagnosis in China, recently completed a financing of RMB 280 million for its diagnostics business segment. The financing round was jointly led by China Resources Pharmaceutical Industry Investment Fund, Shandong Luxin High-tech Industry Co. Ltd., and the Shandong Transportation Industry Development Fund. After serving as exclusive financial advisor for 3D Medicines, the parent company of 3DMed Diagnostic, in its first round of financing, CEC Capital Group continued to serve as exclusive financial advisor for the first round of financing for 3DMed Diagnostic after it was spun-off from the parent company.
-
CancelDate：2020-09
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=529MEDx Translational Medicine (Suzhou) Co., Ltd. (hereinafter referred to as “MEDx Translational Medicine” or the “Company”) recently announced the completion of RMB 350 million in Series B financing. This round of financing was led by existing shareholder Qiming Venture Partners. Followers of the round included Sinopharm Capital, Tsing Song Capital and Broad Resources. Existing investors Quan Capital and Anjie Investment also expanded their holdings within the Company. This round of financing will primarily be used to expand the Company’s translation medicine platform, increase the R&D of diagnostic products, accelerate product registration and sales networks, expand overseas R&D and service capabilities, and expand commercial marketing efforts. The Company is aiming to better support domestic and international pharmaceutical companies in developing innovative drugs and precision medication for cancer patients.
-
CancelDate：2020-09
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=531Following the announcement of the completion of its pre-Series C round of financing in July 2020, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO Technology” or the “Company”) officially announced the completion of over RMB 300 million in Series C financing. This round of financing was led by Loyal Valley Capital. Morningside Group, Shanghai Lingang Economic Development, Sherpa Healthcare Partners, Kunlun Investment, GP Hi-tech Capital, and BioTrack Capital participated as followers in the round. CEC Capital Group has served as the Company’s financial advisor in OBiO Technology’s pre-Series C and Series C rounds of financing, and has helped the Company complete more than RMB 600 million in equity financing within the past six months.
-
CancelDate：2020-09
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=527Fenlai Shangcheng (“Funlike” or the “Company”), a leading domestic supply chain service and social retail enablement platform in China, has recently completed its Series A financing of RMB 100 million. This round of financing was led by Cypress Capital (China) and Great Value Asset led the investment, with several followers participating in the round. With this round of financing, Funlike aims to accelerate the development and optimization of its brands, system tools, logistics and warehousing, after-sales services, marketing, and other capabilities. The Company also plans to expand its urban operation centers and deepen its upstream and downstream channel coverage, ultimately building a supply chain service platform centered on FMCGs.
-
CancelDate：2020-09
http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=534XWPharma, formerly known as XW Laboratories (“XWPharma” or the “Company”), a research and development company focused on the development of innovative drugs for the treatment of central nervous system diseases, has recently announced the completion of its USD 40 million Series C financing round. This round of financing was led by Panacea Ventures. Other participants included CDIB Capital Group, Orient Hontai, and Trinity Innovation Fund. Existing investors Johnson & Johnson Development Corporation (JJDC), WI Harper Group, WuXi AppTec, and KTB Network also participated in the round. Proceeds from this round of financing will be used for the clinical development of two lead projects in the Company’s pipeline, XW10172 and XW10508. XW10172 is a GABAB receptor agonist used to treat sleep disorders caused by narcolepsy and neurodegenerative diseases (such as Parkinson’s disease). XW10508 is a clinical application based on glutamate NMDA receptor antagonism and AMPA receptor activation. The compound will be used to treat major depression and chronic pain diseases.
-
Cancel
Scan to log in to WeChatLog in on phone to use WeChat on Web
京公网安备 11010102004518号